Vaccine update - New vaccine mandates in Queensland

Australia // 30 November, 2021

Australia has a booster vaccination for all adults which began in November 2021. See details in individual news items below.

30 November: The Queensland government has announced mandatory vaccination requirements to be enforced from 17 December. The mandates cover staff at schools and childcare centres, prisons, staff and patrons at hospitality, entertainment and sporting venues, public galleries and libraries as well as visitors at hospitals and aged care facilities.

Nationwide 86.8% of people aged 16 years and over are fully vaccinated.

12 November: The Therapeutic Goods Administration (TGA) has taken a further step towards the use of Moderna's Spikevax COVID-19 vaccine in children aged 6 to 11 years of age. So far the vaccine has provisional approval to be used in children aged 12 and over. "Moderna Australia has now submitted data for provisional approval and the TGA is assessing the use of SPIKEVAX in children 6 to 11 years old. Moderna has also submitted an application to the TGA in relation to the use of SPIKEVAX as a booster dose and this is under evaluation."

Pfizer/BioNTech is now available through community pharmacies, and "all primary care sites around the country will progressively be able to offer all three COVID-19 vaccines approved for use in Australia".

2 November: The Australian Technical Advisory Group on Immunisation (ATAGI) has recommended that a single booster dose of Pfizer/BioNTech be given to adults who completed their primary COVID-19 vaccine course ≥6 months ago. The booster shots will commence from 8 November, "are free and will be available through the primary healthcare network (GPs, community pharmacies, Aboriginal Community Controlled Health Services, and Commonwealth Vaccination Clinics) and state and territory vaccination hubs".

Two more vaccines are recognised by authorities although they are not available in Australia. Covaxin (manufactured by Bharat Biotech, India) and BBIBP-CorV (manufactured by Sinopharm, China) join Coronavac (manufactured by Sinovac, China) and Covishield (manufactured by AstraZeneca, India) to be "'recognised' for the purpose of establishing a traveller's vaccination status".

27 October: The Therapeutic Goods Administration (TGA) has approved Pfizer/BioNTech COVID-19 vaccination boosters for adults. At least 6 months after the completion of a primary course of vaccination with any of the registered vaccines (AstraZeneca, Moderna, Pfizer/BioNTech), the third booster dose of Pfizer/BioNTech can be given. The roll out of the booster programme is expected to commence by 8 November, however the Australian Technical Advisory Group on Immunisation (ATAGI) must first provide its recommendations. Moderna is expected to also apply to the TGA for registration of booster doses.

8 October: The Australian Technical Advisory Group on Immunisation (ATAGI) is recommending that people 12 years and over who are severely immunocompromised be offered a three dose primary vaccination series. The Pfizer/BioNTech, Moderna or Oxford/AstraZeneca vaccine may be used for the third dose, given 2 to 6 months after the second dose.

Nationwide, almost 17 million people (over 65% of the total population) have had one vaccine dose, with 12.4 million (around 48%) fully vaccinated.

1 October: Authorities have announced that all approved vaccines in the country; Pfizer/BioNTech, Moderna and Oxford/AstraZeneca are available to all over the age of 18 years and above. Individuals aged between 12 and 17 years can register for the Moderna or Pfizer/BioNTech vaccine.

20 September: Moderna vaccine has arrived in the country, and has been rolled out initially in pharmacies. The Prime Minister announced "All jurisdictions agreed to integrate an individuals’ record of COVID-19 immunisation history into state and territory check-in apps. The record of COVID-19 immunisation history will be used within these check-in apps as per requirements under state and territory public health orders."

14 September: Authorities have expanded the vaccine eligibility to include everyone aged 12 years and above. Vaccines recommended by the ATAGI are the Pfizer/BioNTech or Moderna.

Businesses can now begin arranging workplace COVID-19 vaccination programmes. The Minister for Health announced "businesses are now able to team up with vaccination providers to administer the jabs to staff at their workplace. Vaccination providers will be able to seek accreditation to administer COVID-19 vaccines at workplaces", known as the "Vaccine Administration Partners Program". The programmes will use Pfizer/BioNTech and Moderna, however AstraZeneca can also be used. The approved providers will be paid a fixed price per vaccine dose by the government. Businesses will negotiate arrangements directly with providers, and patients will not be charged. Full details for applying to the Vaccine Administration Partners Program is available at AusTender - the requirements include the ability to administer a minimum of 500 vaccines per week.

6 September: Everyone aged 16 and over is now eligible for vaccination. The Therapeutic Goods Administration has granted provisional approval for Moderna to be used in children aged 12 to 17 years of age (Moderna was granted provisional approval for use in people aged 18 and over last month).

The UK and Australia have agreed a sharing of 4 million Pfizer/BioNTech doses, with the first of over 450,000 doses arriving on 5 September.

Australia and Singapore have agreed to share doses of COVID-19 vaccines, providing Australia with 500,000 doses of Pfizer/BioNTech now. Australia will provide the same number of doses to Singapore later.

The national no-fault COVID-19 vaccine indemnity scheme has been finalised. "The Scheme will provide Australians with quick access to compensation for COVID-19 claims related to the administration of a Therapeutic Goods Administration approved COVID-19 vaccine delivered through a Commonwealth Government approved program." From today, "Australians who suffer injury and loss of income due to their COVID-19 vaccine will be able to register their intent to claim from the COVID-19 vaccine claims scheme webpage."

27 August: A press release from the Australian Government has recommended vaccination of 12 years and above with the Pfizer/BioNTech COVID-19 vaccine. Priority groups include "Individuals with specified underlying risk conditions, including NDIS participants, All Aboriginal and Torres Strait Islander children,
All children in remote communities, as part of broader community outreach vaccination programs."

The Australian Technical Advisory Group on Immunisation (ATAGI) "has reviewed the evidence and now supports COVID-19 vaccination in all adolescents from 12 years of age."

20 August: A press release from the Prime Minister's office announced that the individuals aged 16 to 39 will be eligible for the COVID-19 Pfizer vaccine from 30 August 2021. The Eligibility Checker will be updated accordingly and will reflect availability for appointments as per the states/territories eligibility. The notice urged people to maintain patience and avoid calling up GPs or vaccine providers regarding the matter. A transcript to the complete speech is also available.

Poland has re-sold 1 million doses of Pfizer to Australia, on a non-profit basis.

9 August: The Prime Minister’s office released a bulletin today announcing the conditional approval of the Moderna vaccine. According to the media release, the Therapeutic Goods Administration (TGA) provided provisional approval for the Moderna vaccine, in adults. So far, the government has secured 25 million doses, and the first million are expected to arrive in September. The TGA is continuing to review data regarding safety in those aged 12 to 17-years-old.

31 July: The Government has provided the conditions under which companies can offer rewards to fully vaccinated people under the national programme. Authorities are encouraging businesses to promote COVID-19 vaccination to their employees, providing a business kit with information and supporting materials.

Organizations are in discussions with authorities to use unallocated supplies of AstraZeneca vaccines to allow corporate vaccination programmes for employees to begin in the near future.

26 July: The major supermarket retailers in NSW have secured access for their workers in "hotspot" outbreak areas. They will have priority access to Pfizer vaccines at the mass vaccination hub at Sydney Olympic Park, with pop-up clinics to be launched at company distribution centres. In Sydney, walk-in vaccination clinics offering AstraZeneca vaccine will soon open.

25 July: The purchase of an additional 85 million doses of Pfizer/BioNTech COVID-19 vaccines has been agreed for delivery in 2022 and 2023. The plan is to enable booster coverage

24 July: Everyone over the age of 18 can choose to receive an AstraZeneca vaccine now. People aged between 18 and 59 are advised to have a discussion with their general practitioner to weigh up the individual risks and benefits, and must provide verbal or written consent.

The Australian Technical Advisory Group on Immunisation (ATAGI) has further clarified its advice on the use of AstraZeneca in people under the age of 60 in Sydney, as well as delaying the second dose of Pfizer/BioNTech from three to six weeks. Due to the current outbreak, and limited supplies of Pfizer/BioNTech the group advises "All individuals aged 18 years and above in greater Sydney, including adults under 60 years of age, should strongly consider getting vaccinated with any available vaccine including COVID-19 Vaccine AstraZeneca.[...] ATAGI also reinforces that the interval between the first and second doses of Comirnaty (Pfizer) is 3-6 weeks, providing flexibility in managing available supplies of vaccines, whilst also noting two doses are required for optimal protection. Spacing Comirnaty (Pfizer) to a routine interval of 6 weeks would allow limited vaccine supplies to be redirected to obtain first dose protection in outbreak areas of greatest need."

In New South Wales, the second dose of Pfizer/BioNTech will be given at up to six weeks, rather than three, so that more people can receive their first dose.

23 July: The Australian Technical Advisory Group on Immunisation (ATAGI) has approved the use of Pfizer/BioNTech in 12-15 year old children. Currently the vaccination programme does not include anyone younger than 16, however authorities will review in light of this approval.

14 July: Due to the COVID-19 outbreak in NSW, and supply constraints of the Pfizer vaccine, authorities have updated their advice on the use of AstraZeneca. The new advice states "In the context of a COVID-19 outbreak where the supply of Comirnaty (Pfizer) is constrained, adults younger than 60 years old who do not have immediate access to Comirnaty (Pfizer) should re-assess the benefits to them and their contacts from being vaccinated with COVID-19 Vaccine AstraZeneca, versus the rare risk of a serious side effect." In addition, the interval before the second dose has been shortened from a maximum of 12 weeks to 8 weeks. In non-outbreak settings, the recommendation for the second dose to be administered at 12 weeks remains.

More vaccination sites have begun operating. There are more than 200 new general practices administering vaccine, and over 500 have been approved to administer Pfizer vaccine (previously general practices were restricted to using AstraZeneca due the more complicated handling and storage requirements for Pfizer). Nationally there are over 6,000 sites providing vaccination services - these include over 5,000 general practices, 136 Commonwealth Vaccination Clinics (CVC), 49 pharmacies, 158 Aboriginal Community Controlled Health Services (ACCHS) and 830 vaccination points administered by the state and territory governments sites. Further sites will be stood up in July - 32 additional general practices and 16 community pharmacies administering AstraZeneca.

Deliveries of Pfizer have been accelerated. One million doses each week are expected to be available from 19 July, compared to the current 300,000 - 350,000 doses per week. A trial of home quarantine, for fully vaccinated travellers who had been vaccinated in Australia, with an Australian approved vaccination, arriving from low and medium risk countries, will be implemented.

In NSW, a new phase of the vaccine rollout has been announced. Teachers and aged care workers in and around outbreak areas have been prioritised, regardless of their age, with a new vaccination hub being established in the area. "NSW Health vaccination clinics and centres will now begin making the AstraZeneca vaccine available to people aged over 40. And NSW will green-light pharmacies across the state to do the same."

28 June: Further measures are being implemented to speed the vaccination rollout. There is an "urgency" due to "new community outbreaks" in several states. Vaccination progress had slowed due to the change in the age group for which AstraZeneca is used. A new "no-fault" indemnity scheme for GPs who administer COVID-19 vaccines (approved by the Therapeutic Goods Administration and approved for use in the COVID-19 programme) is being implemented. In a press conference, the Prime Minister stated "the ATAGI [Australian Technical Advisory Group on Immunisation] advice [...] does not preclude persons under 60 from getting the AstraZeneca vaccine." GPs can continue to administer AstraZeneca to Australians under 60 years of age with informed consent.

An additional 236 General Practitioners (GPs) and some pharmacists in certain rural areas have been approved to administer vaccine.

COVID-19 vaccinations are to be mandatory for residential aged care workers as a condition of working in an aged care facility. All such workers are to have received at least the first dose of a COVID-19 vaccine by mid-September. Under the new Residential Aged Care COVID-19 Employee Vaccination Support Grant, facilities will receive payments to support their staff being vaccinated, such as going off-site to receive vaccination, paid leave if unwell post vaccination, and other expenses such as transport.

In addition, vaccination is now mandatory for all quarantine workers and "all workers directly and indirectly involved in managed quarantine including workers involved in the transport of quarantined individuals". Further advice is being sought on the issue of mandatory vaccination for aviation and interstate freight transport workers, as well as Fly-in-Fly-Out (FIFO) workers in the resource sector.

25 June: The Therapeutic Goods Administration (TGA) has granted provisional approval to the Johnson&Johnson COVID-19 vaccine. The vaccine is approved for individuals 18 years and old. This vaccine however, is not included in the national COVID-19 vaccination program.

17 June: The Australian Technical Advisory Group on Immunisation (ATAGI) now recommends that Pfizer vaccine (Comirnaty) is used in people aged under 60, rather than the AstraZeneca vaccine. Previously, it was reserved for people under the age of 50. "The recommendation is revised due to a higher risk and observed severity of thrombosis and thrombocytopenia syndrome (TTS) related to the use of AstraZeneca COVID-19 vaccine observed in Australia in the 50-59 year old age group than reported internationally and initially estimated in Australia." The complication of unusual blood clots associated with the AstraZeneca vaccine has been reported from a number of countries. Some countries have suspended its use altogether, while many reserve the vaccine for older people.

16 June: In Queensland, some centres on the Gold Coast are providing vaccination to everyone aged 16 and over.

9 June: In the Northern Territory, vaccination is now open to everyone aged 16 and older. In South Australia's regional council areas, residents aged 16 and over are eligible for vaccination. In Western Australia, every one aged 30 and over is eligible for vaccination. In all other areas, vaccination is open to everyone aged 40 and over, and those in certain other groups such as people with underlying health conditions, and travellers with exemptions to leave the country.

The digital vaccination certificate is available following completion of two doses of Pfizer/BioNTech or AstraZeneca, through the online applications myGov or the Express Plus Medicare App.

In regional Queensland, COVID-19 vaccination is being administered in 49 designated pharmacies. "These pharmacies are located in areas where there is not a GP delivering the service."

4 June: From 8 June, across the country, everyone aged 40 and over will be eligible for vaccination. In the Northern Territory, in some areas, including Alice Springs, vaccination is available to people aged 16 and older. South Australia similarly is offering vaccine to everyone aged 16 and older who lives in a regional council area.

Authorities have announced a COVID-19 digital vaccination certificate "will soon be available through the Medicare Express app, with a future digital wallet version to be made available in July. States and territories may consider the potential future value of COVID-19 digital certificates when considering automatic travel exemptions for interstate travel during state-determined lockdowns and travel restrictions."

31 May: Authorities have confirmed the details of eligibility and documentation required for outbound travellers who wish to be vaccinated. "You are eligible for COVID-19 vaccination if you have been granted an Australian Border Force (ABF) travel exemption where your exemption letter states that you are eligible for a COVID-19 vaccination. You are eligible for COVID-19 vaccination until the expiry date of your exemption. If you are aged under 50 years, you can use your travel exemption notification stating you are eligible for COVID-19 vaccination as evidence of your eligibility for vaccination. Applications for travel exemptions are submitted through the ABF’s Travel Exemption Portal

In South Australia, everyone aged 16 and older who lives in a regional council area is eligible to book a COVID-19 vaccination appointment.

People aged 40-49
NSW
- register interest and will be contacted to make an appointment
Queensland - register now and will be contacted when an appointment is available

Victoria - vaccination of people over the age of 40 began on 28 May

13 May: Authorities have agreed to purchase 25 million doses of Moderna vaccine. The vaccine must gain approval from the Australian Therapeutic Goods Administration (ATAGI) before it can be used. It is anticipated that the current formulation of Moderna will be available later this year, and potentially new formulations which are adjusted for variants of SARS-CoV-2 will arrive in 2022.

At the National Cabinet's last meeting, there was an agreement to open vaccination to travellers granted an exemption to leave the country. The details, including the required documentary evidence, are being finalised.

A mass vaccination hub has launched in Sydney, at the Olympic Park. It has the capacity to administer 5,000 vaccinations per day. It is currently using the Pfizer vaccine for healthcare workers, emergency services workers, and quarantine and border workers and their households. It is also providing AstraZeneca for people aged 50 and over. People aged 40-49 can now register interest in receiving Pfizer vaccine.

Victoria has also opened several mass vaccination centres.

1 May: From 3 May, people aged 50 and over can be vaccinated with AstraZeneca vaccine at General Practice Respiratory Clinics, and state and territory vaccination clinics. From 17 May, they can also be vaccinated at participating general practices. The Pfizer/BioNTech vaccine is being prioritised for people under the age of 50. Additional Pfizer hubs are being established.

Over 2,200,000 doses of vaccine have been administered, about half of these have been through general practices.

The government is discussing the possibility of purchasing COVID-19 vaccines from the manufacturer Valneva. Valneva's vaccine candidate is in Phase 3 trials.

19 April: The States and Territories discussed changing the priority groups for vaccination, in view of the change in advice that people under 50 should preferably be vaccinated with Pfizer. The change in advice has meant that many doses of vaccines are not being used, as people over 50 are not currently eligible to be vaccinated. "National Cabinet agreed in-principle to a series of changes to the Australian COVID-19 Vaccination Strategy that will be put forward for approval at the next meeting of National Cabinet including options to bring forward the commencement of vaccinations for over 50 year olds under the Australian COVID-19 Vaccination Strategy priority group 2a, and the readiness of more state and territory-operated vaccination sites including mass vaccination sites, as vaccine supplies increase."

Victoria will open three mass vaccination centres from 21 April. People who are eligible can book an appointment via a call centre or in some cases online.

A total of three cases of thrombosis with thrombocytopenia following AstraZeneca vaccination have now been documented. The second case was in a woman in her 40's in Western Australia who is in a stable condition. The third is a 48-year-old woman with underlying health issues in New South Wales who has died.

11 April: Authorities have made an agreement with Pfizer for an additional 20 million doses of COVID-19 vaccine, on top of the original 20 million agreed doses. The additional vaccine is expected to be available in the final quarter of the year. Current COVID-19 vaccine agreements with Pfizer (40 million doses), AstraZeneca (53.8 million doses), Novavax (51 million doses) and the COVAX facility (25.5 million) are for 170 million doses.

8 April: The Minister for health and Chief Medical Office have issued a statement regarding the ongoing use of the AstraZeneca Vaccine as a result of recommendations by The Australian Technical Advisory Group on Immunisation (ATAGI). After reviewing evidence from Europe and the UK, the Pfizer COVID-19 vaccination is preferred for citizens under the age of 50 years old. The AstraZeneca vaccine will continue to be used for those above 50 years old, those who have had their first vaccination with the AstraZeneca vaccine and where the benefits outweigh the risks.

3 April: The Australian Technical Advisory Group on Immunisation (ATAGI) has noted a case of clotting disorder following AstraZeneca vaccine. Officials mention that this is one case in over 400,000 doses administered till date. Officials have confirmed that there is no change in advice on the use of AstraZeneca vaccine. They have published a notice for consumers to be aware of the common side effects of the vaccine and be alert to severe persistent headache that does not select with painkillers. Authorities are investigating the case further and another review is likely on 7 April.

26 March: The Minister for Health announced that over 830,000 doses of locally-manufactured AstraZeneca COVID-19 vaccine have commenced distribution. It is expected that 500,000 doses will be distributed each week. An additional 159,000 doses of Pfizer vaccine have been received.

25 March: The Australian Technical Advisory Group on Immunisation (ATAGI) has recommended that "vaccination with any COVID-19 vaccine should be deferred for people who have a history of the following rare conditions. This is until further information from ongoing investigations in Europe is available and is only a precautionary measure: people with a confirmed medical history of CVST (cerebral venous sinus thrombosis); and/or people with a confirmed medical history of heparin induced thrombocytopenia (HIT). HIT is an immune-mediated complication of treatment with heparin that affects platelet function. A HIT-like mechanism is being investigated as a potential, but unconfirmed, pathway to CVST post COVID-19 vaccination."

This follows the recent announcement by German and Norwegian doctors that they had discovered antibodies to platelets (a part of the blood that creates clots to stop bleeding) in some of the patients who developed blood clots.

Several countries had suspended and then recommenced vaccination with AstraZeneca following the notification of blood clots.

22 March: Phase 1B of Australia's COVID-19 vaccination program starts today. About 6 million people will be eligible to receive their first dose including Australians aged 70 and over, Aboriginal and Torres Strait Islanders aged 55 and over, younger Australians with underlying health conditions and frontline healthcare workers.

The Therapeutic Goods Administration (TGA) has approved the local manufacture of the AstraZeneca COVID-19 Vaccine by CSL-Seqirus. There are two sites in Melbourne - one is manufacturing, while the other bottles and packages the vaccine. Fifty million doses are to be manufactured in Australia. The first batch is expected to be tested and released in the near future.

18 March: Over 1000 general practices and GP-led respiratory clinics (GPRCs) across the country will commence COVID-19 vaccination from 22 March. People in group 1b, which includes people over 70, healthcare workers who were not in group 1a, and essential service workers (police, defence, fire) and people with underlying health issues are eligible to participate. To arrange vaccination, people need to go to the eligibility checker, which provides a link to the Vaccine Clinic Finder. Many GP practices can only make appointments by telephone, and are not yet ready to take bookings. By the end of April, this is expected to expand to over 4,000 locations,

In relation to the suspension of the use of AstraZeneca vaccines by some countries, the Australian Technical Advisory Group on Immunisation (ATAGI) issued a statement saying "Based on evidence to date, ATAGI do not see any reason to pause use of the AstraZeneca vaccine in Australia." They noted "the rates of thrombotic events are not higher in vaccine recipients than the expected background rate" but are monitoring the situation.

Meanwhile the Therapeutic Goods Administration is reviewing several anaphylactic reactions to the AstraZeneca vaccine in Queensland. All of the reactions were from a single batch of vaccine. ATAGI recommends "people without a previous history of specific or severe allergy should be observed post vaccination for the recommended 15 minute period. Only those with specific allergies or a previous history of anaphylaxis may require vaccination in a facility with medical staff in attendance, and to be observed for 30 minutes following administration of a COVID-19 vaccine dose."

9 March: Phase 1A of the vaccination campaign continues - so far over 86,000 people have received a dose of vaccine. Some supplies of the AstraZeneca vaccine have been received, and the first vaccinations with this brand started in South Australia. However supplies from overseas have been delayed as the European Commission has refused to authorise export of the vaccine. The first doses of locally-produced AstraZeneca vaccine (manufactured onshore by CSL) will be available by the 22 March - the plan is to produce a total of 50 million doses.

In February, a doctor who was vaccinating residents of an aged-care facility in Brisbane inadvertently administered an excessive amount of vaccine.

23 February: Vaccination campaigns kicked off in Australia on 22 February in Australian Capital Territory, New South Wales, Northern Territory, Queensland, South Australia, Victoria and Western Australia. On the first day, there were around 1,300 doses administered in New South Wales, 580 in Victoria and over 200 in Queensland.

Vaccination has begun today in Tasmania

A second batch of 166,000 Pfizer-BioNTech doses was received on 22 February.

19 February: The Phase 1a rollout will commence on 22 February with the Pfizer/BioNTech vaccine. There are 678,000 doses of vaccine available for this phase. The rollout will begin with 16 hospitals and over 190 aged care facilities across the country. State and territory health departments will notify border and quarantine workers (70,000 doses) and frontiine healthcare workers (100,000 doses) when and how to receive their vaccine. Aged and disability care facilities will notify its workers (318,000 doses) and residents (190,000 doses) whether they are vaccinated on site, or at a vaccination hub.

The vaccination hubs are:
Australian Capital Territory: The Canberra Hospital
New South Wales: Royal Prince Alfred Hospital, Westmead Hospital, Liverpool Hospital
Northern Territory: Royal Darwin Hospital
Queensland: Gold Coast University Hospital, Cairns Hospital, Princess Alexandra Hospital
South Australia: Royal Adelaide Hospital, Flinders Medical Centre
Tasmania: Royal Hobart Hospital
Victoria: Monash Medical Centre Clayton, Sunshine Hospital, Austin Health, University Hospital Geelong
Western Australia: Perth Children's Hospital

COVID-19 vaccines are free for everyone living in Australia.

16 February: An initial shipment of over 142,000 doses of the Pfizer/BioNTech vaccine arrived in Australia on 15 February. The country has ordered 20 million doses of this vaccine. Authorities will perform batch testing, before the national vaccination campaign rolls out from 22 February. Phase 1A includes vaccinating healthcare and frontline border workers and the most vulnerable people.

In addition, the Therapeutics Goods Administration has granted provisional approval to the Oxford-AstraZeneca vaccine. This vaccine can be given to people 18 years and over, with two doses between 4 and 12 weeks apart.

This is the second approved vaccine, following on the Pfizer-BioNTech approval in late January.

5 February: In an information pack on COVID-19 vaccination for residents in residential aged facilities and their carers, the Australian Technical Advisory Group on Immunisation (ATAGI) advises "that the preferred minimum interval between administration of either the Pfizer/BioNTech or the University of Oxford/AstraZeneca vaccines and any influenza vaccine is 14 days. This is the current precautionary advice."

4 February: A further 10 million doses of the Pfizer/BioNTech vaccine have been secured in Australia. The total number of doses of Pfizer/BioNTech secured is 20 million. This vaccine was provisionally approved for use in Australia in January. The vaccine rollout will begin in late February, and the additional doses will be available in the second half of this year.

LATEST NEWS

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. …
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. …